AHL
TVTX icon

Abel Hall LLC’s Travere Therapeutics TVTX Stock Holding History

Abel Hall LLC’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$352K Buy
+6,195
New +$275K 0.06% 395

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Abel Hall LLC's TVTX Position: Q2 2026 in Review

Abel Hall LLC opened a new position in Travere Therapeutics (TVTX) in Q2 2026: 6,195 shares worth $352K. The stake represents 0.06% of the portfolio and ranks #395 among its holdings.

321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Abel Hall LLC held 6,195 shares of Travere Therapeutics worth $352K as of Q2 2026.
  • Travere Therapeutics was a new Abel Hall LLC position in Q2 2026.
  • Travere Therapeutics made up 0.06% of Abel Hall LLC's portfolio in Q2 2026, its #395 holding.
  • 321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Abel Hall LLC's 13F filing for Q2 2026, filed 24 Jul 2026.